Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof

Patent metadata

Field	Value
Publication number	US-9255136-B2
Application number	US-201113639374-A
Country	US
Kind code	B2
Filing date	Apr 8, 2011
Priority date	Apr 8, 2010
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

Polypeptide The present invention relates to polypeptides fragments derived from the protein TLT-1 have been isolated and are useful in pharmaceutical preparations used for the treatment of inflammatory conditions such as sepsis.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a therapeutically effective amount of at least one polypeptide consisting of 12 to 16 amino acids comprising SEQ ID NO: 9 and at least one pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein said at least one polypeptide consists of an amino acid sequence as set forth in SEQ ID NO: 9.

3. An isolated polypeptide consisting of 12 to 16 amino acids comprising SEQ ID NO:9.

4. The isolated polypeptide of claim 3 , wherein said polypeptide consists of an amino acid sequence as set forth in SEQ ID NO: 9.

5. A pharmaceutical composition comprising a therapeutically effective amount of at least one polypeptide consisting of 6, 7, 8, 9, 10 or 11 amino acids from the amino acid sequence SEQ ID NO: 4, wherein said at least one polypeptide comprises SEQ ID NO: 6.

6. An isolated polypeptide consisting of 6, 7, 8, 9, 10 or 11 amino acids from the amino acid sequence SEQ ID NO: 4, wherein said polypeptide comprises SEQ ID NO: 6.

7. The pharmaceutical composition of claim 5 , wherein said polypeptide consists of an amino acid sequence as set forth in SEQ ID NO: 6.

8. The isolated polypeptide of claim 6 , wherein said polypeptide consists of an amino acid sequence as set forth in SEQ ID NO: 6.

9. A pharmaceutical composition comprising a therapeutically effective amount of at least one polypeptide consisting of 6, 7, 8, 9, or 11 amino acids from the amino acid sequence SEQ ID NO: 4, wherein said at least one polypeptide comprises SEQ ID NO: 7 or SEQ ID NO: 8.

10. The pharmaceutical composition of claim 9 , wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 7 or SEQ ID NO: 8.

11. An isolated polypeptide consisting of 6, 7, 8, 9, or 11 amino acids from the amino acid sequence SEQ ID NO: 4, wherein said polypeptide comprises SEQ ID NO: 7 or SEQ ID NO: 8.

12. The isolated polypeptide of claim 11 , wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 7 or SEQ ID NO: 8.

Assignees

• Gibot Sebastien
• Derive Marc
• Inst Nat Sante Rech Med
• Univ Lorraine

Inventors

• Gibot Sebastien
• Derive Marc

Classifications

• C07K14/70503 Primary

  Immunoglobulin superfamily · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title